Envelope-to: diana@transocean.com
Delivery-date: Fri, 14 Jul 2017 08:04:13 -0700
Reply-To: brooke.pugh@maharajaworld.com
To: diana@transocean.com
Subject: You need to read this if you have ever used Onglyza.
Mime-Version: 1
From: B Pugh <brooke.pugh@maharajaworld.com>
Message-ID: <zp.U7KA.HJ9i8lWyLQzdpkDxPIAn@mail.maharajaworld.com>
Content-Type: multipart/alternative; boundary="9exS8HsErUkZ.C1mJLPc.vcQ5Dt7s8a"
Date: Fri, 14 Jul 2017 11:04:10 -0400
 
 Content preview:    ** Onglyza Settlement   ** [...] 
 
 Content analysis details:   (2.8 points, 3.0 required)
 
  pts rule name              description
 ---- ---------------------- --------------------------------------------------
  0.0 URIBL_BLOCKED          ADMINISTRATOR NOTICE: The query to URIBL was blocked.
                             See
                             http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block
                              for more information.
                             [URIs: maharajaworld.com]
 -0.0 SPF_HELO_PASS          SPF: HELO matches SPF record
 -0.0 SPF_PASS               SPF: sender matches SPF record
  0.0 HTML_MESSAGE           BODY: HTML included in message
  0.0 HTML_FONT_LOW_CONTRAST BODY: HTML font color similar or identical to
                             background
  0.8 BAYES_50               BODY: Bayes spam probability is 40 to 60%
                             [score: 0.5000]
  2.0 RDNS_NONE              Delivered to internal network by a host with no rDNS
  0.0 T_HTML_TAG_BALANCE_CENTER Malformatted HTML
X-Spam-Flag: NO

--9exS8HsErUkZ.C1mJLPc.vcQ5Dt7s8a
Content-type: text/plain; charset=UTF-8
Content-transfer-encoding: 8bit

 
** 
------------------------------------------------------------

Onglyza Settlement

 
** 
------------------------------------------------------------

You may be entitled to financial compensation. For a free case review, click below. (http://www.maharajaworld.com/hdjai9d8sa7yhda/dshahdas8uhdsa) 
 CLICK HERE (http://www.maharajaworld.com/isjdasdkaidja/jdsiaduahds) 

 
Onglyza is a Type 2 diabetes medication used by millions of adult Americans to improve glycemic control. Onglyza has recently been linked to heart failure. 

A report by the US Food and Drug Administration found that Onglyza can increase the risk of heart failure by 27%. This places patients at a higher risk of fatal heart attack. The FDA has issued a warning about Onglyza?s risks. AstraZeneca, the manufacturer of Onglyza, had previously never warned Type 2 diabetes patients or their physicians about these risks. 

If you or a loved one has suffered injury or death through the use of Onglyza, CLICK HERE (http://www.maharajaworld.com/98udjakdsa/dhjasidaujda) for a FREE legal case review.

Legal professionals are standing by to review your case and determine if you qualify. There is limited time to pursue a claim, so don't delay. 

This Site does not provide medical advice, diagnosis or treatment. It is recommended that you consult with your healthcare provider to discuss the benefits and risks with continuing or stopping any current medical treatment or prescriptions.

Disclaimer: THIS IS A PAID ATTORNEY/ADVOCATE ADVERTISEMENT. This Site is a group advertisement and a fee is paid for by participating attorneys and advocates. The site is not an attorney referral service or prepaid legal services plan. This Site does not make any representation to the qualifications, expertise or credentials of participating attorneys/advocates and does not represent that quality is better than services performed by other attorneys/advocates. Any information you submit to this Site may not be protected by attorney-client privilege. An automated matching system will match each request with a member attorney/advocate representing the specific geography. A list of participating attorneys will be mailed free of charge to members of the public upon request.

Click Here To Stop Emails (http://tab.maharajaworld.com/ihsad8usadja/bdasidasuj) 
Or Write To:
JGA, 1120 Finch Avenue West, Suite 701-1861 Toronto, Ontario, M3J 3H7

--9exS8HsErUkZ.C1mJLPc.vcQ5Dt7s8a
Content-Type: text/html; charset=UTF-8
Content-transfer-encoding: 8bit

<!DOCTYPE html>
<html>


<head>
 <meta name="robots" content="noindex, nofollow" />
 <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
 <meta http-equiv="content-type" content="text/html; charset=utf-8" />

 <title>Onglyza</title>

 <meta name="description" content="" />
 <meta name="keywords" content="" />


 <meta property="og:locale" content="en_US" />
 <meta property="og:type" content="article" />
 <meta property="og:title" content="OnglyzaSettlement" />
 <meta property="og:description" content="Onglyza is a Type 2 diabetes medication used by millions of adult Americans to improve glycemic control. Onglyza has recently been linked to heart failure.  A report by the US Food and Drug Administration found that Onglyza can increase the risk of heart failure by 27%. This places patients at a higher risk of fatal heart attack.  The FDA has issued a warning about Onglyza?s risks. AstraZeneca, the manufacturer of Onglyza, had previously never warned Type 2 diabetes patients or their physicians about these risks.  If you or a loved one has suffered injury or death through the use of Onglyza, fill out the form for a FREE legal case review." />
 <meta property="og:site_name" content="OnglyzaSettlement" />
 <meta property="og:url" content="http://medicalsettlement.net/onglyza" />


<style>
	.simeonov {
		border:2px;
		border-style:solid;
		width: 600px;
		border-color:#0061D5;
		border-radius: 20px;
		border-spacing:600px;

	}
		a {
    color: #0061D5;
	text-decoration: none;
	}
	a,a:hover,a:focus {
    text-decoration:none;
    outline:none;
	}
</style>
 
 
 <meta name="viewport" content="width=device-width, initial-scale=1.0" id="mobile-viewport">
 
 
</head><center>
<body><div class="simeonov">
 <div id="i-page" class="page page2 ">
 <div class="page-block" id="page_block_header">
 <div class="border-holder">
 <div class="block-inner">
 <div class="page-element widget-container page-element-type-headline widget-headline" id="element-1">
 <div class="contents">
 <h1><p style=" "><b>Onglyza Settlement</b><br></p></h1>
 </div>
 </div>
 </div>
 </div>
 </div> 
 <div class="page-block" id="page_block_below_fold">
 <div class="color-overlay"></div>
 <div class="border-holder"> 
 <div class="block-inner">
 <div class="page-element widget-container page-element-type-text widget-text " id="element-2">

 <div class="contents" style="margin-bottom: 20px;">
 <h1>
 <p style="font-size:26px;"><font color="#c7830b"><a href="http://www.maharajaworld.com/hdjai9d8sa7yhda/dshahdas8uhdsa"><b>You may be entitled to financial compensation. For a free case review, click below.</b></a><br></font>
 <div id="clickbutton">
 <p><div class="round-button"><div class="round-button-circle"><a href="http://www.maharajaworld.com/isjdasdkaidja/jdsiaduahds" class=round-button>CLICK HERE</a></div></div></p></div>
 </p></h1>
 </div>
 <div class="contents">
 <img border="0" src="http://lets.maharajaworld.com/8aidjnasdha/bdjsaidauh" width="78" height="193" align="center" alt="Show"/><p><br/></br/>Onglyza is a Type 2 diabetes medication used by millions of adult Americans to improve glycemic control. Onglyza has recently been linked to heart failure. 
 <br/>
 </p>
 <p style=" ">
 <br>
 </p>
 <p style=" ">A report by the US Food and Drug Administration found that Onglyza can increase the risk of heart failure by 27%. This places patients at a higher risk of fatal heart attack.  The FDA has issued a warning about Onglyza?s risks. AstraZeneca, the manufacturer of Onglyza, had previously never warned Type 2 diabetes patients or their physicians about these risks. 
 <br>
 </p>
 <p style=" ">
 <br>
 </p>
 <p style=" ">If you or a loved one has suffered injury or death through the use of Onglyza, <a href="http://www.maharajaworld.com/98udjakdsa/dhjasidaujda">CLICK HERE</a> for a FREE legal case review.<br>
 </p>
 <p style=" ">
 <br>
 </p>
 </div>
 </div>
 </div>
 </div>
 </div>
 <div class="page-block" id="page_block_footer">
 <div class="color-overlay"></div>
 <div class="block-inner">
 <div class="page-element widget-container page-element-type-text widget-text " id="element-17">
 <div class="contents">
 <p><font color="#ffffff">Legal professionals are standing by to review your case and determine if you qualify. <b>There is limited time to pursue a claim, so don't delay. </b><br></font>
 </p>
 </div>
 </div>
 </div>
 </div>
 <div class="page-block" id="page-block-xh4dt3kz5o">
 <div class="color-overlay"></div>
 <div class="border-holder">
 <div class="block-inner">
 <div class="page-element widget-container page-element-type-text widget-text " id="element-13">

 <div class="contents">
 <p style="text-align: center; "><font color="#040406">This Site does not provide medical advice, diagnosis or treatment. It is recommended that you consult with your healthcare provider to discuss the benefits and risks with continuing or stopping any current medical treatment or prescriptions.<br><br>Disclaimer: THIS IS A PAID ATTORNEY/ADVOCATE ADVERTISEMENT. This Site is a group advertisement and a fee is paid for by participating attorneys and advocates. The site is not an attorney referral service or prepaid legal services plan. This Site does not make any representation to the qualifications, expertise or credentials of participating attorneys/advocates and does not represent that quality is better than services performed by other attorneys/advocates. Any information you submit to this Site may not be protected by attorney-client privilege. An automated matching system will match each request with a member attorney/advocate representing the specific geography. A list of participating attorneys will be mailed free of charge to members of the public upon request.</font>
 </p>
 </div>
 </div>

 </div>
 </div>
 </div>
 </div>
 <br><br><br>
	</div></body></center>
<center><br><br><br><br>
 <a href="http://tab.maharajaworld.com/ihsad8usadja/bdasidasuj">Click Here To Stop Emails</a><br>
 Or Write To:<br>
JGA, 1120 Finch Avenue West, Suite 701-1861 Toronto, Ontario, M3J 3H7
</html>

--9exS8HsErUkZ.C1mJLPc.vcQ5Dt7s8a--